Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Gets UK Grant for Stem Cell Tools Project

NEW YORK (GenomeWeb News) – Cellzome today said that it will lead a project that has received a €1.1 million ($1.5 million) grant from the UK's Technology Strategy Board to develop tools that better characterize human stem cells.

Heidelberg, Germany-based Cellzome will collaborate with Pfizer's Neusentis unit, the University of Sheffield, and Plasticell on the project, which will use Cellzome's Episphere technology to identify protein "fingerprints" that predict potentially deleterious changes in stem cells. The grant covers two years of funding.

The firm announced earlier this year that it would collaborate with Neusentis on studying epigenetic mechanisms involved in stem cell differentiation.

Cellzome noted that this grant is the third it has received this year leveraging its chemoproteomics platform. The other two include its part in the Blueprint collaboration to decipher epigenomes of the hematopoietic system, under which it will receive €1.2 million, and its efforts in the Orchid project, under which it is using its platform to help identify new treatments for tuberculosis.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.